Materials for Diabetes Therapeutics by Bratlie, Kaitlin M, York, Roger L., Invernale, Michael A., Langer, Robert S, Anderson, Daniel Griffith

Get full text
Get full text
Get full text

Microbiome therapeutics — Advances and challenges by Mimee, Mark, Citorik, Robert J, Lu, Timothy K

“…In order to leverage the close associations between microbes and their host, development of therapeutics targeting the microbiota has surged in recent years. …”
Get full text

InVivo Therapeutics® Corporation by Reynolds, Francis M., M.B.A. Massachusetts Institute of Technology

Get full text

Broad-Spectrum Antiviral Therapeutics by Rider, Todd H., Zook, Christina E., Boettcher, Tara L., Wick, Scott T., Pancoast, Jennifer S., Zusman, Benjamin D.

“…Currently there are relatively few antiviral therapeutics, and most which do exist are highly pathogen-specific or have other disadvantages. …”
Get full text

Partitioning of cancer therapeutics in nuclear condensates

“…Here, we investigated whether condensates concentrate small-molecule cancer therapeutics such that their pharmacodynamic properties are altered. …”
Get full text

Partitioning of cancer therapeutics in nuclear condensates by Klein, Isaac A., Boija, Ann, Afeyan, Lena K., Hawken, Susana Wilson, Fan, Mengyang, Dall'Agnese, Alessandra, Oksuz, Ozgur, Henninger, Jonathan E., Shrinivas, Krishna, Sabari, Benjamin R., Sagi, Ido, Clark, Victoria E., Platt, Jesse M., Kar, Mrityunjoy, McCall, Patrick M., Zamudio, Alicia V., Manteiga, John C., Coffey, Eliot L., Li, Charles H., Hannett, Nancy M., Guo, Yang Eric, Decker, Tim-Michael, Lee, Tong Ihn, Zhang, Tinghu, Weng, Jing-Ke, Taatjes, Dylan J., Chakraborty, Arup, Sharp, Phillip A., Chang, Young Tae, Hyman, Anthony A., Gray, Nathanael S., Young, Richard A.

“…Here, we investigated whether condensates concentrate small-molecule cancer therapeutics such that their pharmacodynamic properties are altered. …”
Get full text

Stabilization of Therapeutic Proteins by Chu, Jhih-Wei, Yin, Jin, Mazyar, Oleg, Goh, Lin-Tang, Yap, Miranda G.S., Wang, Daniel I.C., Trout, Bernhardt L.

Get full text

Rett Syndrome: Genes, Synapses, Circuits, and Therapeutics by Banerjee, Abhishek, Castro, Jorge, Sur, Mriganka

“…Here, we discuss key questions and recent studies describing animal models, cell-type specific functions of methyl-CpG binding protein 2 (MeCP2), defects in neural circuit plasticity, and attempts to evaluate possible therapeutic strategies for RTT. We also discuss how genes, proteins, and overlapping signaling pathways affect the molecular etiology of apparently unrelated neuropsychiatric disorders, an understanding of which can offer novel therapeutic strategies for a range of autism spectrum disorders (ASDs).…”
Get full text
Get full text

Microbial therapeutics: New opportunities for drug delivery by Jimenez, Miguel, Langer, Robert S, Traverso, Carlo Giovanni

“…With >40 clinical trials underway, we are nearing the first FDA-approved live microbial therapeutic. Here, Giovanni Traverso, MIT and Harvard Medical School Assistant Professor, and colleagues Miguel Jimenez and Institute Professor Robert Langer from MIT discuss the significant challenges of administering live microorganisms to patients and the opportunities for drug delivery of these new complex therapeutics.…”
Get full text

RNA therapeutics – The potential treatment for myocardial infarction by Chu, Hunghao, Kohane, Daniel S, Langer, Robert

“…© 2016 The Japanese Society for Regenerative Medicine. RNA therapeutics mainly control gene expression at the transcript level. …”
Get full text

Accelerating glioblastoma therapeutics via venture philanthropy by Siah, Kien Wei, Xu, Qingyang, Tanner, Kirk, Futer, Olga, Frishkopf, John J, Lo, Andrew W

“…Using estimates from domain experts at the National Brain Tumor Society (NBTS), we analyze the performance of a portfolio of 20 assets being developed for GBM, diversified across different development phases and therapeutic mechanisms. We find that the portfolio generates a 14.9% expected annualized rate of return. …”
Get full text

mRNA therapeutics: beyond vaccine applications by Bhat, Balkrishen, Karve, Shrirang, Anderson, Daniel G

Get full text

Delivery of macromolecule therapeutics via jetting in the gastrointestinal tract by Arrick, Graham(Graham Philip)

Get full text

Synthetic biology approaches for engineering bacteria as living therapeutics by Triassi, Alexander John.

Get full text

Technological Improvement Rates and Evolution of Energy-Based Therapeutics by Basnet, Subarna, Magee, Christopher L.

Get full text

Synthetic biology in the clinic: engineering vaccines, diagnostics, and therapeutics by Tan, Xiao, Letendre, Justin H, Collins, James J, Wong, Wilson W

“…Here, we highlight applications of synthetic biology in vaccine development, molecular diagnostics, and cell-based therapeutics, emphasizing technologies approved for clinical use or in active clinical trials. …”
Get full text

Kirigami-inspired stents for sustained local delivery of therapeutics by Babaee, Sahab, Shi, Yichao, Abbasalizadeh, Saeed, Tamang, Siddartha, Hess, Kaitlyn, Collins, Joy E, Ishida, Keiko, Lopes, Aaron, Williams, Michael, Albaghdadi, Mazen, Hayward, Alison M, Traverso, Giovanni

“…Implantable drug depots have the capacity to locally meet therapeutic requirements by maximizing local drug efficacy and minimizing potential systemic side effects. …”
Get full text

The Pivotal Role of Chemical Modifications in mRNA Therapeutics by Liu, Albert, Wang, Xiao

“…<jats:p>After over a decade of development, mRNA has recently matured into a potent modality for therapeutics. The advantages of mRNA therapeutics, including their rapid development and scalability, have been highlighted due to the SARS-CoV-2 pandemic, in which the first two clinically approved mRNA vaccines have been spotlighted. …”
Get full text

A Novel Approach to Equitable Distribution of Scarce Therapeutics by Rubin, Emily, Dryden-Peterson, Scott L, Hammond, Sarah P, Lennes, Inga, Letourneau, Alyssa R, Pathak, Parag, Sonmez, Tayfun, Ünver, M Utku

“…A significantly higher proportion of patients offered mAb therapy were socially vulnerable (27.0%) than would have been the case if the infusion appointments had been allocated using a pure lottery system without a vulnerable reserve (19.8%), and a significantly higher proportion of patient who received infusions were socially vulnerable (25.3%) than would have been the case if the infusion appointments had been allocated using a pure lottery system (17.6%) INTERPRETATION: Our health system experience demonstrates that a reserve system with a lottery for tiebreaking is a viable way to distribute scarce therapeutics when enhancing access for certain groups is desirable.…”
Get full text

Development of novel diagnostics and therapeutics for amyotrophic lateral sclerosis by Townsend, Seth A. (Seth Alan)

Get full text